COMMUNIQUÉS West-GlobeNewswire

-
Michael DePerro, MD, Offers Minimally Invasive Gynecomastia Surgery Technique
12/10/2018 -
NovuHealth Named No. 5 on Minneapolis/St. Paul Business Journal's Fast 50 List for Two Years Running
12/10/2018 -
Innovation Pharmaceuticals Brilacidin as a Novel Inhibitor of Phosphodiesterase 4 (PDE4) Supports its Potential to Treat Autoimmune and Inflammatory Diseases; Company Invited to Present at Upcoming Crohn’s & Colitis Foundation Conference
12/10/2018 -
RAMSAY GENERALE DE SANTE : supplement to the offer document in respect of the public offer to the shareholders of Capio
12/10/2018 -
RAMSAY GENERALE DE SANTE : complément au document d'offre relatif à l'offre publique d'achat faite aux actionnaires de Capio
12/10/2018 -
Trident Brands Inc. Entering US Hemp CBD Market with Brain Armor® R3 Supplement
12/10/2018 -
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 septembre 2018
12/10/2018 -
US Patent Trial & Appeal Board (PTAB) Upholds Silence Patent by Denying First of Five Patent Grant Review Applications Filed by Alnylam
12/10/2018 -
Silence Therapeutics Announces Receipt of a New European Notice of Intention to Grant a Patent and the Launch of an Interim European Injunction Application against Onpattro™
12/10/2018 -
Exagen Announces Launch of Novel Biomarker PC4d Associated with Thrombosis in Lupus
12/10/2018 -
Radius Health to Announce Third Quarter 2018 Financial Results, Host Conference Call and Live Webcast on November 1, 2018
12/10/2018 -
MPX Expands Maryland Footprint With Opening of Baltimore Dispensary
12/10/2018 -
MRI Interventions and Monteris Medical Announce Collaboration to Develop Next-Generation Head Fixation Frames for Laser Ablation Neurosurgery
12/10/2018 -
Equillium Announces Pricing of Initial Public Offering
12/10/2018 -
Scythian Biosciences Applauds the UK Government’s Decision to Legalize Medical Cannabis
12/10/2018 -
Foamix to Present Clinical Data From Study FX2017-22 at the Fall Clinical Dermatology Conference
12/10/2018 -
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $220 Million of Common Stock
12/10/2018 -
Auris Medical to provide update on intranasal betahistine program on Wednesday, October 17, 2018
12/10/2018 -
Emblem to supply British Columbia and Saskatchewan markets with high quality cannabis
12/10/2018
Pages